| Iovance–Cellectis: gene editing technology, 202001– collab + license ww excl for TILs in several cancer indications |
2020-01-12 |
| Alderaan Biotechnology–Advent France Biotechnology: investment, 202001 financing round Series A totalling €18.5m incl existing investor AFB |
2020-01-09 |
| Alderaan Biotechnology–Medicxi: investment, 202001 financing round Series A totalling €18.5m incl new investor Medicxi |
2020-01-09 |
| Alderaan Biotechnology–SEVERAL: investment, 202001 financing round Series A €18.5m with Advent France Biotechnology + Medicxi |
2020-01-09 |
| Sanofi–Nurix Therapeutics: protein degradation drugs, 202001– collab strategic ww $55m upfront + $2.5m milestones using DELigase platform |
2020-01-09 |
| Riemser–Esteve: investment, 202001– acquisition €na of Riemser from Ardian by Esteve |
2020-01-08 |
| VectivBio–France (govt): investment, 202001 1st financing round totalling $35m incl Bpifrance + Inserm Transfer Initiative |
2020-01-07 |
| VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. |
2020-01-07 |
| Pharma Omnium–Novo Group: investment, 202001 investment €7m by Novo REPAIR Impact fund into Mutabilis |
2020-01-06 |
| Augustine Therapeutics–SEVERAL: investment, 201912 seed financing round €4.2m from V-Bio Ventures + PMV + Advent France + Gemma Vrisius + VIB |
2019-12-16 |
| Aelis Farma–NewCap: public relations, 201912 service existent by NewCap |
2019-12-13 |
| Aelis Farma–SEVERAL: grant, 201912c research grants totalling €9m from various organisations incl US NIDA |
2019-12-13 |
| Aelis Farma–SEVERAL: investment, 201912 financing round €11m incl Region Nouvelle Aquitaine + Inserm Transfert Initiative + Bpifrance |
2019-12-13 |
| Inscripta–SEVERAL: investment, 201912 financing round Series D $125m led by Paladin Capital Group |
2019-12-10 |
| Synthorx–Sanofi: investment, 201912– acquisition $2.35b cash tender offer at $68/share ANNOUNCED |
2019-12-09 |
| ImCheck Therapeutics–Agent Capital: investment, 201912 financing round Series B totalling €48m incl new + co-investor Agent Capital |
2019-12-04 |
| ImCheck Therapeutics–Alexandria Real Estate: investment, 201912 financing round Series B totalling €48m incl new + co-investor Alexandria Venture |
2019-12-04 |
| ImCheck Therapeutics–Boehringer: investment, 201912 financing round Series B totalling €48m incl existing + co-investor BIVF |
2019-12-04 |
| ImCheck Therapeutics–Dechert: legal services, 201912 supply service Dechert LLP acted as legal counsel for €48m Series B round of ImCheck |
2019-12-04 |
| ImCheck Therapeutics–Dentons: legal services, 201912 supply service Dentons Europe acted as legal counsel for €48m Series B round of ImCheck |
2019-12-04 |
| ImCheck Therapeutics–France (govt): investment, 201912 financing round Series B totalling €48m incl co-lead investor Bpifrance InnoBio 2 + LV funds |
2019-12-04 |
| ImCheck Therapeutics–Gimv: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Gimv |
2019-12-04 |
| ImCheck Therapeutics–Idinvest Partners: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Idinvest Partners |
2019-12-04 |
| ImCheck Therapeutics–Kurma: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Kurma Partners |
2019-12-04 |
| ImCheck Therapeutics–Life Sciences Partners: investment, 201912 financing round Series B totalling €48m incl existing + co-investor LSP |
2019-12-04 |
| ImCheck Therapeutics–Pfizer: investment, 201912 financing round Series B totalling €48m incl co-lead investor Pfizer Ventures |
2019-12-04 |
| ImCheck Therapeutics–SEVERAL: investment, 201912 financing round Series B €48m co-led by Bpifrance + Pfizer Ventures |
2019-12-04 |
| ImCheck Therapeutics–Trophic Communications: public relations, 201912 service existent IR + PR US + EU by Trophic |
2019-12-04 |
| ImCheck Therapeutics–Wellington Partners: investment, 201912 financing round Series B totalling €48m incl new + co-investor Wellington Partners |
2019-12-04 |
| Diabeloop–SEVERAL: investment, 201912 financing round Series B €22m led by Cemag Invest |
2019-12-02 |
| Innate Pharma–Rentschler: biologics contract manufacturing, –201912 supply service production lacutamab for clinical trials |
2019-12-02 |
| Sanofi–Ligand: transgenic animal technology, 201912– license ww for OmniAb platform |
2019-12-02 |
| ECBF–SEVERAL: investment, 201911– European Circular Bioeconomy Fund aims to raise €250m incl up to €100m from EIB |
2019-11-29 |
| Tissium–SEVERAL: investment, 201911 financing round Series B €38.75m from EIB + French investors |
2019-11-20 |
| Acticor Biotech–SEVERAL: investment, 201911 financing round Series B extension €7m led by new investorGO Capital bringing Series B to €22.3m |
2019-11-06 |
| AVCare–Acticor Biotech: investment, 201911 acquisition 100% of AVCare by Acticor Biotech |
2019-11-06 |
| Urania Therapeutics–Advent France Biotechnology: investment, 201911 seed financing round totalling €3.53m incl lead investor AFB |
2019-11-06 |
| Urania Therapeutics–Andrew Lloyd Associates: public relations, 201911 service existent by ALA |
2019-11-06 |
| Urania Therapeutics–Capital Grand Est: investment, 201911 seed financing round totalling €3.53m incl co-investor Cap Innov’Est |
2019-11-06 |
| Urania Therapeutics–Novalix: drug development services, 201911– supply of drug development services to Urania by Novalix |
2019-11-06 |
| Urania Therapeutics–SEVERAL: investment, 201911 seed financing round €3.53m led by Advent France Biotechnology + incl Cap Innov’Est |
2019-11-06 |
| BOOSTER Consortium–Acticor Biotech: glenzocimab, 201911– project partner with ph2 study of glenzocimab in combi with mechanical thrombectomy |
2019-11-05 |
| BOOSTER Consortium–France (govt): grant, 201911c– ANR RHU grant €9.9m for personalised management of stroke in emergency situations |
2019-11-05 |
| Poxel–IPF Partners: credit, 201911–201412 bond loan up to €30m in three tranches 11/19 + 3/20 + 12/21 |
2019-11-05 |
| Pieris–SEVERAL: investment, 201911 private placement $32m w 9.015m units (shares + warrants) at $3.55/unit led by BVF Partners |
2019-11-04 |
| genOway–Institut Pasteur: transgenic anmials, 201910– license extension from IP + Cellectis to genOway to take legal actions against infringement |
2019-10-30 |
| Innate Pharma–SEVERAL: investment, 201910 pirvate placement €22.13m with 4.45m ordinary shares at €4.97/share |
2019-10-21 |
| Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund |
2019-10-17 |
| Aeovian Pharmaceuticals–Apollo Ventures: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Apollo Health Ventures |
2019-10-03 |
| Aeovian Pharmaceuticals–Evotec: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Evotec |
2019-10-03 |
| Aeovian Pharmaceuticals–SEVERAL: investment, 201910 financing round Series A $37m led by VenBio + Sofinnova Investments |
2019-10-03 |
| Aeovian Pharmaceuticals–Sofinnova: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor Sofinnova Investments |
2019-10-03 |
| Aeovian Pharmaceuticals–VenBio: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor VenBio Partners |
2019-10-03 |
| Cellectis–Lonza: cell therapy contract manufacturing, 201910– supply UCART cell therapy candidates by Lonza in Geleen (NL) |
2019-10-01 |
| Tacalyx–SEVERAL: investment, 201909 seed financing round €7m co-led by BIVF + Kurma Partners |
2019-09-25 |
| Innate Pharma–SEVERAL: investment, 201909–201910 US IPO $54.5m with 9.922m ADSs at $5.5/ADS + listing of ADSs at Nasdaq Global Select Market |
2019-09-20 |
| Themis Bioscience–SEVERAL: investment, 201909 financing round Series D €40m co-led by Farallon Capital + Hadean Ventures |
2019-09-18 |
| Celyad–Ulysse Communication: public relations, 201909 service existent for Europe by Ulysse |
2019-09-16 |
| Inotrem–Andera Partners: investment, 201909 financing round Series B totalling €39m incl exisiting + co-investor Andera Partners |
2019-09-12 |
| Inotrem–BioMedPartners: investment, 201909 financing round Series B totalling €39m incl exisiting + co-investor BioMedInvest |
2019-09-12 |
| Inotrem–Invus Group: investment, 201909 financing round Series B totalling €39m incl co-investor Invus |
2019-09-12 |
| Inotrem–Morningside: investment, 201909 financing round Series B totalling €39m incl lead investor Morningside Ventures |
2019-09-12 |
| Inotrem–SEVERAL: investment, 201909 financing round Series B €39m led by Morningside Ventures |
2019-09-12 |
| Inotrem–Sofinnova: investment, 201909 financing round Series B totalling €39m incl exisiting + co-investor Sofinnova Partners |
2019-09-12 |
| Ermium Therapeutics–SEVERAL: investment, 201909 financing round Series A €6.3m from Domain Therapeutics + Kurma Partners + Idinvest + SATT Erganeo |
2019-09-11 |
| Keranova–SEVERAL: investment, 201909 2nd financing round €24m incl Mérieux Equity Partners + Supernova Invest + Arbevel + TI-invest |
2019-09-10 |
| Pharvaris–SEVERAL: investment, 201909 financing round Series B $66m led by Foresite Capital |
2019-09-10 |
| iStar Medical–SEVERAL: investment, 201905 financing round Series C €40m led by LSP + Gimv |
2019-09-05 |
| TreeFrog Therapeutics–EU (govt): grant, 201909– Horizon 2022 SME Instrument Program Phase 2 Grant €2.4m |
2019-09-05 |
| TreeFrog Therapeutics–France (govt): grant, 201909–2020 grant €450k from Bpifrance i-Nov Innovation Challenge Phase 2 |
2019-09-05 |
| HiFiBio–Delian Capital: investment, 201908 financing round Series C totalling $67m incl new + co-investor Delian Capital |
2019-08-28 |
| HiFiBio–Gilead: investment, 201908 financing round Series C totalling $67m incl new + co-investor Kite |
2019-08-28 |
| HiFiBio–Hanne Capital: investment, 201908 financing round Series C totalling $67m incl new + co-investor Hanne Capital |
2019-08-28 |
| HiFiBio–IDG Capital: investment, 201908 financing round Series C totalling $67m incl new + lead investor IDG Capital |
2019-08-28 |
| HiFiBio–Legend Star Capital: investment, 201908 financing round Series C totalling $67m incl existing + co-investor Legend Star Capital |
2019-08-28 |
| HiFiBio–Lyfe Capital: investment, 201908 financing round Series C totalling $67m incl existing + co-investor Lyfe Capital |
2019-08-28 |
| HiFiBio–Sequoia Capital: investment, 201908 financing round Series C totalling $67m incl existing + co-investor Sequoia Capital China |
2019-08-28 |
| HiFiBio–SEVERAL: investment, 201908 financing round Series C $67m led by new investor IDG Capital |
2019-08-28 |
| HiFiBio–VI Ventures: investment, 201908 financing round Series C totalling $67m incl existing + co-investor VI Ventures |
2019-08-28 |
| Blue Heron–Eurofins: investment, 201908 acquisition of Blue Heron Biotech by Eurofins Genomics LLC |
2019-08-06 |
| Alizé Pharma–SEVERAL: investment, 201907 financing round Series A €67m of Alizé Pharma 3 led by LSP |
2019-07-31 |
| Twist Bioscience–Imagene: nucleic acid storage technology, 201907– supply service DNA encapsulation using DNAshell technology |
2019-07-25 |
| Infarco–Keensight Capital: investment, 201907 acquisition of Infarco’s majority stake in 3P Biopharmaceuticals by Keensight |
2019-07-23 |
| Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| BiomX–SEVERAL: investment, 201907–201910 listing at NYSE via SPAC merger with $60m in trust account |
2019-07-17 |
| Pyxis Oncology–SEVERAL: investment, 201907 financing round Series A $22m led by Leaps by Bayer |
2019-07-17 |
| AM-Pharma–SEVERAL: investment, 201907 financing round €116m co-led by LSP + Andera Partners |
2019-07-16 |
| BPCE–Illumina: business services, 201907– collab Illumina Accelerator UK + Seventure Partners to provide funding + lab services + coaching to startups |
2019-07-16 |
| Sofinnova–Illumina: business services, 201907– collab Illumina Accelerator UK to provide funding + lab services + coaching to startups |
2019-07-16 |
| Genmab–Blink Biomedical: therapeutic antibodies, 201907– license to use CD47 Abs in DuoBodies $2.25m upfront + up to $200m per product plus royalties |
2019-07-12 |
| Microphyt–CEA Industrie: investment, 201907 financing round totalling €28.5m incl existing + co-investor Supernova Invest |
2019-07-11 |
| Microphyt–Demeter: investment, 201907 financing round totalling €28.5m incl existing + co-investor Demeter Partners |
2019-07-11 |
| Microphyt–France (govt): investment, 201907 financing round totalling €28.5m incl new + co-lead investor Bpifrance SPI Fund |
2019-07-11 |
| Microphyt–Irdi Soridec: investment, 201907 financing round totalling €28.5m incl existing + co-investor Irdi Soridec |
2019-07-11 |
| Microphyt–iXO Private Equity: investment, 201907 financing round totalling €28.5m incl new + co-investor iXO Private Equity |
2019-07-11 |
| Microphyt–Safilaro: investment, 201907 financing round totalling €28.5m incl new + co-investor Sofilaro |
2019-07-11 |
| Microphyt–SEVERAL: investment, 201907 financing round €28.5m co-led by Sofinnova Partners + Bpifrance SPI Fund |
2019-07-11 |
| Microphyt–Sofinnova: investment, 201907 financing round totalling €28.5m incl new + co-lead investor Sofinnova Partners |
2019-07-11 |
![[LSF] Life-Sciences-France.com - The French Life Sciences Web Portal](/images/basics/lsf-life-sciences-france-portal-logo-2019.png){kind=logo}
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lsus-life-sciences-usa-com.jpg)
Date![Picture [iito] LSUS iitoLifeScience Transatlantic Life Sciences 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
